Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Vaccines01:30

Cancer Vaccines

1.2K
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
1.2K
Cancer Prevention02:59

Cancer Prevention

8.6K
Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
8.6K
Cancer Prevention02:59

Cancer Prevention

3.0K
3.0K
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

6.5K
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
6.5K
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

5.9K
5.9K
Mechanisms of Retrovirus-induced Cancers01:51

Mechanisms of Retrovirus-induced Cancers

7.1K
Retroviruses are RNA viruses that have been shown to cause cancers in diverse species, including chickens, mice, cats, and monkeys. The RNA genomes of these viruses are first reverse-transcribed into single and then double-stranded DNA (dsDNA) copies. This dsDNA called proviral DNA then integrates into the host genome. Subsequently, the host cell transcribes the proviral DNA in concert with the chromosomal DNA. This leads to the production of viral RNA and proteins that assemble at the host...
7.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Giant planum sphenoidale meningioma: rationale for Dolenc's step in the pterional approach.

Neurosurgical focus: Video·2026
Same author

mGem: AAV, from almost a virus to an awesome vector-or is it?

mBio·2026
Same author

Total and Neutralizing Antibody Seroprevalence of Hepatotropic Adeno-Associated Virus Among Healthy and Hemophilia A or B Population from India.

Human gene therapy·2025
Same author

Changing Spectrum of Invasive Fungal Infections of the Anterior Skull Base.

Journal of neurological surgery. Part B, Skull base·2024
Same author

Outcomes following surgical clipping of re-ruptured previously untreated intracranial aneurysms.

Neurosurgical review·2024
Same author

AAV vectors for long-term gene therapy of hemophilia B: Are we there yet?

Molecular therapy : the journal of the American Society of Gene Therapy·2024
Same journal

Genome Editing for Familial Hemophagocytic Lymphohistiocytosis: Design Principles, Challenges, and Translational Perspectives.

Human gene therapy·2026
Same journal

Lilly, Ascidian Launch Up-to-$1.9B RNA Exon Editor Collaboration.

Human gene therapy·2026
Same journal

Hyperthermia-Enhanced Adeno-Associated Virus Gene Therapy: Mechanisms, Delivery Technologies, and Translational Potential.

Human gene therapy·2026
Same journal

Adeno-Associated Virus Gene Therapy Translation: Lessons from Early Regulatory Meetings.

Human gene therapy·2026
Same journal

In Remembrance of Professor Zelig Eshhar: <i>A Life Committed to CAR-T</i>.

Human gene therapy·2026
Same journal

<i>In Vivo</i> Genome Editing Approach to Disrupt Hydroxyacid Oxidase 1 for the Treatment of Primary Hyperoxaluria Type 1.

Human gene therapy·2026
See all related articles

Related Experiment Video

Updated: Mar 12, 2026

High-Efficiency Transduction of Liver Cancer Cells by Recombinant Adeno-Associated Virus Serotype 3 Vectors
19:02

High-Efficiency Transduction of Liver Cancer Cells by Recombinant Adeno-Associated Virus Serotype 3 Vectors

Published on: March 22, 2011

13.9K

AAV Infection: Protection from Cancer.

Arun Srivastava1, Barrie J Carter2

  • 11 Division of Cellular and Molecular Therapy, Departments of Pediatrics and Molecular Genetics and Microbiology, Powell Gene Therapy Center; Genetics Institute; University of Florida College of Medicine , Gainesville, Florida.

Human Gene Therapy
|November 12, 2016
PubMed
Summary
This summary is machine-generated.

Adeno-associated virus 2 (AAV2) genome integration does not cause hepatocellular carcinoma (HCC). Evidence shows AAV2 is non-pathogenic, possesses anticancer activity, and has a protective role against cervical cancer.

Keywords:
DNA integrationliver cancerrecombinant AAV vectorswild-type AAV2

More Related Videos

Author Spotlight: Improved Method for Production and Purification of Adeno-Associated Viral Vectors
09:12

Author Spotlight: Improved Method for Production and Purification of Adeno-Associated Viral Vectors

Published on: April 5, 2024

4.7K
Efficient Gene Knockdown in the Liver via Intrasplenic Injection of Adeno-Associated Virus Serotype 8 (AAV8)-Delivered Small Hairpin RNA
04:29

Efficient Gene Knockdown in the Liver via Intrasplenic Injection of Adeno-Associated Virus Serotype 8 (AAV8)-Delivered Small Hairpin RNA

Published on: November 1, 2024

1.1K

Related Experiment Videos

Last Updated: Mar 12, 2026

High-Efficiency Transduction of Liver Cancer Cells by Recombinant Adeno-Associated Virus Serotype 3 Vectors
19:02

High-Efficiency Transduction of Liver Cancer Cells by Recombinant Adeno-Associated Virus Serotype 3 Vectors

Published on: March 22, 2011

13.9K
Author Spotlight: Improved Method for Production and Purification of Adeno-Associated Viral Vectors
09:12

Author Spotlight: Improved Method for Production and Purification of Adeno-Associated Viral Vectors

Published on: April 5, 2024

4.7K
Efficient Gene Knockdown in the Liver via Intrasplenic Injection of Adeno-Associated Virus Serotype 8 (AAV8)-Delivered Small Hairpin RNA
04:29

Efficient Gene Knockdown in the Liver via Intrasplenic Injection of Adeno-Associated Virus Serotype 8 (AAV8)-Delivered Small Hairpin RNA

Published on: November 1, 2024

1.1K

Area of Science:

  • Virology
  • Oncology
  • Hepatology

Background:

  • Conflicting reports suggest adeno-associated virus 2 (AAV2) genome integration may induce hepatocellular carcinoma (HCC).
  • AAV2 is widely prevalent in the human population, with approximately 90% seropositivity.
  • Previous research indicates AAV2 possesses anticancer properties.

Purpose of the Study:

  • To critically evaluate the evidence linking AAV2 genome integration to cancer induction.
  • To present a historical perspective on the role of AAV infection in cancer etiology.

Main Methods:

  • Review of existing scientific literature and clinical trial data.
  • Analysis of epidemiological evidence regarding AAV2 and cancer.
  • Historical account of AAV's role in disease.

Main Results:

  • AAV2 is characterized as a non-pathogenic virus.
  • Epidemiological data suggests a protective effect of AAV2 against cervical carcinoma.
  • Extensive clinical trials using various AAV serotypes have not reported any cancer development.

Conclusions:

  • The assertion that AAV2 genome integration causes HCC is contradicted by substantial evidence.
  • AAV2 demonstrates a lack of oncogenic potential and may even have oncostatic properties.
  • Current clinical applications of AAV vectors are considered safe with respect to cancer risk.